2,264 press releases in English indexed under biotech & pharma.
LAS VEGAS, Oct. 14, 2026 -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced results from Late-Breaking Clinical Trial sessions at VIVA 2026, held at Bellagio...
FORT LEE, N.J., Oct. 14, 2026 -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients with cancer, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug rivoceranib, an oral VEGF-TKI, in combination with camrelizumab, an anti-PD-1 antibody, as a first-line systemic treatment option for unresectable or metastatic hepatocellular carcinoma (uHCC).
In this free webinar, learn how synthesis strategies can support the development of increasingly complex peptide conjugates. The featured speaker will discuss route selection, conjugation, purification and analytical methods across peptide-drug, radionuclide, oligonucleotide and...
� New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure � Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups � Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn's disease with perianal fistula in more than 20 years Johnson & Johnson today announce... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=362822
NeOnc (NASDAQ:NTHI) is strengthening its boardroom, as its clinical-development progress seeks to advance treatments for some of the most difficult cancers
Why Legacy Pathology Archives Matter for Rare-Disease Research Mon, 10/19/2026 - 08:15 Body Why it matters Rare-disease research needs larger, richer historical datasets Digitized archives make decades of evidence searchable Historical tissue can reveal patterns previously missed Pathology archives often contain decades of clinically valuable information that is difficult to access in its original format. Glass slides may reveal evidence of disease patterns and support diagnostic decisions and tissue characteristics that were essential at the time of creation, but as scientific research data they are difficult to search, share and study at scale. As digital pathology matures, those archives are increasingly being viewed differently: not simply as storage, but as valuable research assets. Archives hold more than history This shift is significant because some of the most important questions in medicine cannot be answered with a small sample set. Rare diseases, unusual presentations and long-term retrospective analysis often require access to large collections of historical material. When slides are digitized, they become easier to review, compare, and organize for broader scientific use. Most importantly, not all slides need to be collocated for research as the data can be shared digitally. What was once a physical archive can begin to function as a structured digital dataset. This is where ScanVan™ excels. ScanVan is Leidos’ high-throughput whole-slide digitization platform, designed to bring scanning capability directly to the archive and help convert large volumes of glass slides into digital assets without requiring the collection to be moved off-site. In that sense, ScanVan is not the story itself; it is the operational example of how large-scale archive digitization can happen in practice. The opportunity is impactful for hospital systems and pharmaceutical organizations that are interested in retrospective research, biomarker discovery and future AI-enabled analysis. Digital pathology makes it easier to examine archived tissue in a consistent format, identify patterns across cases and connect specimen-level information to the larger research environment. The larger and more organized the archive, the more useful it becomes for research teams trying to understand rare conditions, compare historical samples or generate hypotheses for future studies. Unlocking value that’s already there A platform like ScanVan supports high-volume digitization in a way that is practical for large, complex archives. The work still has to be done carefully—with strong attention to image quality, chain of custody and operational control—but once the archive is digitized, it becomes a resource that can be used in new ways. In that sense, legacy pathology archives represent an untapped source of scientific value. They are already rich with information. Digitization simply makes that information easier to see, study and apply. For health systems, the question is no longer whether the archive has value. The question is how to unlock it. ScanVan by the numbers Developed in collaboration with the University of Pittsburgh’s Computational Pathology and AI Center of Excellence, ScanVan is designed for collections ranging from thousands to millions of slides. Based on 12-hour scanning days, Monday through Friday, the platform can digitize: More than 16,000 slides per week More than 67,000 slides per month More than 800,000 slides per year These figures demonstrate the operational scale required to turn a legacy archive into a usable research resource. Three things to remember Digitized slides can be shared and studied without physically collocating pathology collections Archive digitization requires strong image quality, chain-of-custody and operational controls ScanVan enables high-volume slide digitization while keeping pathology archives on-site LEARN MORE ABOUT SCANVAN Canonical URL https://www.leidos.com/insights/why-legacy-pathology-archives-matter-rare-disea… Featured Image Type of Content Article
PHILADELPHIA, Oct. 14, 2026 -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the company will attend the upcoming 2026 Jefferies Global Healthcare Conference in London on November 18, 2026.
WATERTOWN, Mass., Oct. 14, 2026 -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the company will participate in a panel during Chardan’s 10th Annual Healthcare Conference on October 20, 2026. Details below:
HOUSTON, Oct. 14, 2026 -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan’s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET.
The Artificial Intelligence in Precision Medicine Market is entering a high-growth phase as healthcare providers and pharmaceutical companies increasingly use AI to understand disease biology, [read full press release...]
Microvascular Therapeutics, Inc. (“MVT”), a clinical-stage biotechnology company developing next-generation ultrasound imaging and therapeutic technologies, today announced that it has been selected to present in the ACQUICON 2026 Deal Room on Tuesday, October 20, 2026, from 12:30–1:30 p.m. Mountain Time at the Karen Gail Miller Conference Center in Salt Lake City. [PR.com]
Sean Michaels has completed a new book, "One Couple, Two Badges," a gripping account of two DEA agents whose partnership transformed from professional collaboration into an unbreakable bond forged in danger. Beginning as independent operatives working in tandem against street-level drug distribution, these agents soon recognized that dismantling the infrastructure at ground level would never achieve lasting [PR.com]